Mesenchymal stem cells/marrow stromal cells (MSCs) are attractive for applications ranging from research and development to use in clinical therapeutics. However, the most commonly studied MSCs, adult bone marrow MSCs (A-MSCs), are limited by significant donor variation resulting in inconsistent expansion rates and multilineage differentiation capabilities. We have recently obtained permission to isolate pediatric MSCs (P-MSCs) from surplus iliac crest bone chips. Here, we developed a simple and easily replicable isolation protocol yielding P-MSCs, which adhere to MSC defining guidelines. After confirming immunophenotypic marker expression, we compared expansion rates, senescence, morphology, and trilineage differentiation of P-MSCs to A-MSCs for multiple donors. We found P-MSCs have faster in vitro replication, consistently show significantly lower senescence, and are capable of more reproducible multilineage differentiation than A-MSCs. We, therefore, believe P-MSCs are a promising candidate for use in research applications and potentially as part of an allogeneic therapeutic treatment.

differentiation, immunomodulation, marrow stromal cells, mesenchymal stem cells, MSC immunophenotype, pediatric mesenchymal stem cells, senescence,
Tissue Engineering - Part C: Methods
no subscription
Department of Oral and Maxillofacial Surgery

Knuth, C.A, Kiernan, C.H. (Caoimhe H.), Palomares Cabeza, V. (Virginia), Lehmann, J, Witte-Bouma, J, ten Berge, D, … Farrell, E. (2018). Isolating Pediatric Mesenchymal Stem Cells with Enhanced Expansion and Differentiation Capabilities. Tissue Engineering - Part C: Methods, 24(6), 313–321. doi:10.1089/ten.tec.2018.0031